Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Wolfe Research

Stock analysts at Wolfe Research began coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a “peer perform” rating on the stock.

Other research analysts have also issued reports about the stock. Guggenheim lifted their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Jefferies Financial Group boosted their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, The Goldman Sachs Group boosted their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $326.25.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $245.39 on Friday. The company has a market capitalization of $7.17 billion, a PE ratio of 35.82 and a beta of 0.49. The company has a fifty day moving average of $267.34 and a 200-day moving average of $229.81. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $107.11 million for the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. On average, equities analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the sale, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 129,164 shares of company stock valued at $34,538,578 over the last quarter. 13.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently modified their holdings of the business. Greenline Wealth Management LLC acquired a new stake in Krystal Biotech in the fourth quarter valued at approximately $34,000. Sound Income Strategies LLC raised its holdings in shares of Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the period. Bessemer Group Inc. lifted its holdings in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after buying an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.